Literature DB >> 21460745

Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma.

Jorrit J Hofstra1, Alexander P Vlaar, Paul Knape, Dave P Mackie, Rogier M Determann, Goda Choi, Tom van der Poll, Marcel Levi, Marcus J Schultz.   

Abstract

BACKGROUND: Pulmonary coagulopathy is intrinsic to pneumonia and other forms of acute lung injury. We hypothesized patients with burn injuries and inhalation trauma to have similar alterations in pulmonary coagulation and fibrinolysis.
METHODS: We performed a prospective study on changes in pulmonary and systemic thrombin generation and fibrinolytic activity in patients with burn injuries and inhalation trauma requiring mechanical ventilation. Nondirected bronchial lavage was performed on alternate days. Patients requiring mechanical ventilation for nonpulmonary reasons who did not meet the North American European Consensus Conference criteria for acute lung injury functioned as control patients.
RESULTS: We studied 13 patients with burn injuries and inhalation trauma and 15 control patients. On admission, patients with burn injuries and inhalation trauma showed a significant increase in thrombin generation in the airways compared with control patients, as reflected by increased lavage fluid levels of thrombin-antithrombin complexes and fibrin degradation products, and decreased lavage fluid levels of activated protein C and antithrombin. Simultaneously, burn patients showed a significant decrease in fibrinolytic activity, as reflected by decreased lavage fluid levels of plasminogen activator activity. Pulmonary coagulopathy persisted throughout the period of mechanical ventilation and was accompanied by similar changes in systemic coagulation and fibrinolysis. There was no significant correlation between changes in coagulation and fibrinolysis and the extent of burn injury.
CONCLUSIONS: Patients with burn injuries and inhalation trauma requiring mechanical ventilation show a distinct and sustained procoagulant and antifibrinolytic shift in the pulmonary compartment. Pulmonary coagulopathy could be an important therapeutic target in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460745     DOI: 10.1097/TA.0b013e31820f85a7

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  15 in total

1.  Blood utilization in patients with burn injury and association with clinical outcomes (CME).

Authors:  Rommel P Lu; Feng-Chang Lin; Shiara M Ortiz-Pujols; Sasha D Adams; Herbert C Whinna; Bruce A Cairns; Nigel S Key
Journal:  Transfusion       Date:  2012-12-24       Impact factor: 3.157

2.  Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation.

Authors:  Raymond C Rancourt; Aftab Ahmad; Livia A Veress; Jacqueline S Rioux; Rhonda B Garlick; Carl W White
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

3.  Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome.

Authors:  Sebastian Rehberg; Yusuke Yamamoto; Linda E Sousse; Collette Jonkam; Robert A Cox; Donald S Prough; Perenlei Enkhbaatar
Journal:  J Trauma Acute Care Surg       Date:  2014-01       Impact factor: 3.313

4.  Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification.

Authors:  Masato Yuasa; Nicholas A Mignemi; Jeffry S Nyman; Craig L Duvall; Herbert S Schwartz; Atsushi Okawa; Toshitaka Yoshii; Gourab Bhattacharjee; Chenguang Zhao; Jesse E Bible; William T Obremskey; Matthew J Flick; Jay L Degen; Joey V Barnett; Justin M M Cates; Jonathan G Schoenecker
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

5.  Endothelial cell-specific anticoagulation reduces inflammation in a mouse model of acute lung injury.

Authors:  Jian Lou; Yue Hu; Min-Dan Wu; Luan-Qing Che; Yin-Fang Wu; Yun Zhao; Bao-Ping Tian; Zheng-Qiang Bao; Chen Zhu; Yan-Ping Wu; Lu-Lu He; Chun-Xue Bai; Jian Zhou; Song-Min Ying; Wen Li; Zhi-Hua Chen; Da-Xin Chen; Anthony Dorling; Hua-Hao Shen
Journal:  Acta Pharmacol Sin       Date:  2018-11-16       Impact factor: 6.150

Review 6.  Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.

Authors:  Jenny Juschten; Pieter R Tuinman; Nicole P Juffermans; Barry Dixon; Marcel Levi; Marcus J Schultz
Journal:  Ann Transl Med       Date:  2017-11

7.  Contribution of damage-associated molecular patterns to transfusion-related acute lung injury in cardiac surgery.

Authors:  Marcella C A Müller; Pieter R Tuinman; Alexander P Vlaar; Anita M Tuip; Kelly Maijoor; Achmed Achouiti; Cornelis Van t Veer; Margreeth B Vroom; Nicole P Juffermans
Journal:  Blood Transfus       Date:  2014-01-02       Impact factor: 3.443

8.  Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study.

Authors:  Yara Backes; Koenraad F van der Sluijs; Anita M Tuip de Boer; Jorrit Jan Hofstra; Alexander P J Vlaar; Rogier M Determann; Paul Knape; David P Mackie; Marcus J Schultz
Journal:  Crit Care       Date:  2011-11-16       Impact factor: 9.097

Review 9.  Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis.

Authors:  Gerie J Glas; Ary Serpa Neto; Janneke Horn; Amalia Cochran; Barry Dixon; Elamin M Elamin; Iris Faraklas; Sharmila Dissanaike; Andrew C Miller; Marcus J Schultz
Journal:  Ann Intensive Care       Date:  2016-04-16       Impact factor: 6.925

10.  HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial.

Authors:  Gerie J Glas; Johannes Muller; Jan M Binnekade; Berry Cleffken; Kirsten Colpaert; Barry Dixon; Nicole P Juffermans; Paul Knape; Marcel M Levi; Bert G Loef; David P Mackie; Manu Malbrain; Marcus J Schultz; Koenraad F van der Sluijs
Journal:  Trials       Date:  2014-03-25       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.